Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.
@WABAC : "Did some minor tax-lost harvesting selling FYLD and IHDG while I still had a little to the plus side." One ETF on the plus side & one on the minus side ? Or had sold a previous winner(s
@WABAC : "Did some minor tax-lost harvesting selling FYLD and IHDG while I still had a little to the plus side." One ETF on the plus side & one on the minus side ? Or had sold a previous winner(s
Just curious, Derf
One was up 5%, and the other was up 4%, since purchase. Lots of dividends down the drain obviously, but I don't see much prospect for improvement in those funds for some time to come.
MOAT position sold; I had owned this etf in various amounts since 2012, but have been shifting away from it for several months. Beneficiaries have been CGDV, PVAL, and TCAF.
MOAT position sold; I had owned this etf in various amounts since 2012, but have been shifting away from it for several months. Beneficiaries have been CGDV, PVAL, and TCAF.
Did you get a chance to write to VanEck about the comprehensive index?
Pfizer (PFE) is now yielding nearly 7% dividend (if they do not cut!), in case you are into return on investment. How fortunes have changed in such a short time for this company that presumably saved us from near extinction!
Pfizer (PFE) is now yielding nearly 7% dividend (if they do not cut!), in case you are into return on investment. How fortunes have changed in such a short time for this company that presumably saved us from near extinction!
Pfizer (PFE) is now yielding nearly 7% dividend (if they do not cut!), in case you are into return on investment. How fortunes have changed in such a short time for this company that presumably saved us from near extinction!
Viagra?
You mean it saved us from near extinction? Interesting thought.
Income investors in this forum do not seem to be drawn to PFE; may be they are more concerned about return of investment than we give them credit for.
"President-elect Donald Trump announced on Nov. 14 that he is nominating Robert F. Kennedy Jr. to be secretary of the Department of Health and Human Services under his new administration in 2025. RFK Jr. has strong views on public health and, if confirmed, could use his position to make changes at several of the 13 HHS divisions. In our Nov. 8 note, we discussed the potential tailwinds of a Trump administration, including possible repeal of the Medicare negotiation provision in the Inflation Reduction Act, less Federal Trade Commission scrutiny of acquisitions, and a likely continuation of lower corporate taxes. However, if RFK’s nomination is confirmed, we expect more “wild card” headwinds to the industry will come to fruition. As the HHS covers the US Food and Drug Administration and the Centers for Disease Control and Prevention, an HHS secretary skeptical of vaccine and obesity drug benefits could work to erode public trust, put up roadblocks for approval of new vaccines, and prevent the CDC from recommending any vaccines that make it through the approval process. With less federal guidance, we think it is possible certain states could waver in support of broad mandates for childhood vaccines. All of these could weigh on sales of vaccines in the US, including covid vaccine makers Moderna and BioNTech and big biopharma vaccine makers like GSK (we model 14% of GSK revenue from US vaccine sales in 2024), Pfizer (12%), Merck (9%), and Sanofi (6%)."
Have purchased the following callable Agency Bonds from MMkt acct:
3130B3MS9 - 30-yr 6.25% (1st call date 2/25) IRA and taxable 3133ERB34 - 7-yr 5.125% (1st call date 5/25) IRA 3133ERB26 - 7-yr 5.0% (only call date posted 11/25) IRA
I've been doing to same @Level5 for much of this year, buying higher yielding long term callable bonds where you can still get at least 5.5+% until called. I just put an order in for a 10 year from DEUTSCHE BK yielding 5.75% at call. The next call isn't for 2 years, 11/29/2026.
I've been doing to same @Level5 for much of this year, buying higher yielding long term callable bonds where you can still get at least 5.5+% until called. I just put an order in for a 10 year from DEUTSCHE BK yielding 5.75% at call. The next call isn't for 2 years, 11/29/2026.
Adding another 1000s of T-C to my income account. GTC order partially filled today.
If called next year, that'd be an extra $5K cap gain per 1000s tranche, which would be nice. Otherwise I'm happy to continue taking the QDI every quarter.
Thanks. do they charge 0.1% ($1 for every $1K face amount) in transaction fees?
I do not currently have a single Agency bond as every one of them I bought got called. I lost a 6% and a 5.6% for redemptions in the last couple of days.
@Old_Joe, to be honest. I don't know the timing between order submittal and actual filled status. I have had a couple of these buys sit in 'open' status for days until accepted, but I have never had one not go through. Accepted date may be "First Settlement Date 11/29/2024", shown in the summary description. Not sure.
@BaluBalu, agree, agency bonds never seem to get past the first call date for me (but to be clear, the bond I mentioned above is not a gov. agency bond. It's a German bank bond).
I have found when reviewing the available lists on Schwab, you need to 1) look at the 'yield to worst and the 'yield to call'. Those can be different than the advertised 'yield to maturity'. 2) when reviewing Schwab's lists, the longest 'next call date' isn't always the highest yield choice shown at the top of the lists. More often than not, you have to search down the list and give up some advertised 'yield to maturity' to extend the time to 'next call date'.
Hope I didn't confuse you with the added criteria I use.
Comments
One ETF on the plus side & one on the minus side ? Or had sold a previous winner(s
Just curious, Derf
Good luck to all
Decisions, decisions.
Income investors in this forum do not seem to be drawn to PFE; may be they are more concerned about return of investment than we give them credit for.
"President-elect Donald Trump announced on Nov. 14 that he is nominating Robert F. Kennedy Jr. to be secretary of the Department of Health and Human Services under his new administration in 2025. RFK Jr. has strong views on public health and, if confirmed, could use his position to make changes at several of the 13 HHS divisions. In our Nov. 8 note, we discussed the potential tailwinds of a Trump administration, including possible repeal of the Medicare negotiation provision in the Inflation Reduction Act, less Federal Trade Commission scrutiny of acquisitions, and a likely continuation of lower corporate taxes. However, if RFK’s nomination is confirmed, we expect more “wild card” headwinds to the industry will come to fruition. As the HHS covers the US Food and Drug Administration and the Centers for Disease Control and Prevention, an HHS secretary skeptical of vaccine and obesity drug benefits could work to erode public trust, put up roadblocks for approval of new vaccines, and prevent the CDC from recommending any vaccines that make it through the approval process. With less federal guidance, we think it is possible certain states could waver in support of broad mandates for childhood vaccines. All of these could weigh on sales of vaccines in the US, including covid vaccine makers Moderna and BioNTech and big biopharma vaccine makers like GSK (we model 14% of GSK revenue from US vaccine sales in 2024), Pfizer (12%), Merck (9%), and Sanofi (6%)."
3130B3MS9 - 30-yr 6.25% (1st call date 2/25) IRA and taxable
3133ERB34 - 7-yr 5.125% (1st call date 5/25) IRA
3133ERB26 - 7-yr 5.0% (only call date posted 11/25) IRA
If called next year, that'd be an extra $5K cap gain per 1000s tranche, which would be nice. Otherwise I'm happy to continue taking the QDI every quarter.
CUSIP 25161FZX9
I do not currently have a single Agency bond as every one of them I bought got called. I lost a 6% and a 5.6% for redemptions in the last couple of days.
@MikeM- Thank you very much for this suggestion.
OJ
ATT preferred stock. Symbol might be different on your brokerage, but it's the 'C' variant.
@BaluBalu, agree, agency bonds never seem to get past the first call date for me (but to be clear, the bond I mentioned above is not a gov. agency bond. It's a German bank bond).
I have found when reviewing the available lists on Schwab, you need to 1) look at the 'yield to worst and the 'yield to call'. Those can be different than the advertised 'yield to maturity'. 2) when reviewing Schwab's lists, the longest 'next call date' isn't always the highest yield choice shown at the top of the lists. More often than not, you have to search down the list and give up some advertised 'yield to maturity' to extend the time to 'next call date'.
Hope I didn't confuse you with the added criteria I use.